A Prospective Randomized Comparison of Concurrent Chemoradiation with Neoadjuvant and Adjuvant Chemotherapy with Concurrent Chemoradiation Alone for Locally Advanced Carcinoma Cervix

Abstract Aims: The aim of this study was to compare concurrent chemoradiation along with neoadjuvant and adjuvant chemotherapy versus concurrent chemoradiation alone in locally advanced cervical cancer regarding treatment response and toxicities. Subjects and Methods: A randomized control study was done on 116 patients with locally advanced carcinoma cervix (Stage IIB to IIIB) registered between January 2014 and February 2015. Patients were randomly divided to receive either one cycle of cisplatin/5-fluorouracil neoadjuvant chemotherapy and two cycles of the same adjuvant chemotherapy with concurrent chemoradiation with weekly cisplatin (Arm A) or only concurrent chemoradiation (Arm B). All patients received three fractions of high-dose-rate intracavitary brachytherapy after completion of the external radiation. Results: A higher proportion of the patients of chemotherapy arm achieved complete response (94%) as compared to the nonchemotherapy arm (56%), and this was statistically significant. There was a trend toward more treatment-related acute toxicity with chemotherapy. Conclusions: These results have corroborated the view that if neoadjuvant and adjuvant chemotherapies are added to concurrent chemoradiation, it could further the effects of concurrent chemoradiation for patients with locally advanced cancer of the uterine cervix.

[1]  D. Alberts,et al.  Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  B. Kim,et al.  Salvage chemotherapy with a combination of paclitaxel, ifosfamide, and cisplatin for the patients with recurrent carcinoma of the uterine cervix , 2005, International Journal of Gynecologic Cancer.

[3]  K. Šitum,et al.  Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: results of a phase II study. , 2005, International journal of radiation oncology, biology, physics.

[4]  P. Grigsby,et al.  Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Choy,et al.  Chemoradiation and adjuvant chemotherapy in cervical cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  L. Coia,et al.  Pretreatment and treatment factors associated with improved outcome in squamous cell carcinoma of the uterine cervix: a final report of the 1973 and 1978 patterns of care studies. , 1991, International journal of radiation oncology, biology, physics.

[7]  L. Coia,et al.  The patterns of care outcome study for cancer of the uterine cervix results of the second national practice survey , 1990, Cancer.

[8]  C Vrousos,et al.  Radiotherapy alone in carcinoma of the intact uterine cervix according to G. H. Fletcher guidelines: a French cooperative study of 1383 cases. , 1988, International journal of radiation oncology, biology, physics.

[9]  J. Crissman,et al.  Histopathologic Prognostic Factors in Stage II and III Squamous Cell Carcinoma of the Uterine Cervix , 1987, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[10]  Y. Fu,et al.  Histologic types and prognosis of cancers of the uterine cervix. , 1979, International journal of radiation oncology, biology, physics.